<DOC>
	<DOC>NCT01392001</DOC>
	<brief_summary>This observational study will evaluate the glucocorticoid sparing effect after 12 months of treatment with RoActemra/Actemra (tocilizumab) in patients with rheumatoid arthritis. Data will be collected for 12 months after the initiation of treatment with RoActemra/Actemra from patients who had been on treatment with &gt;5 mg prednisone or equivalent for at least 3 months .</brief_summary>
	<brief_title>An Observational Study of Glucocorticoid Use in Patients With Rheumatoid Arthritis on Treatment With RoActemra/Actemra (Tocilizumab)</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Glucocorticoids</mesh_term>
	<criteria>Adult patients, &gt;/= 18 years of age Patients with rheumatoid arthritis for whom the rheumatologist decided to introduce RoActemra Patients taking more than 5 mg/day of oral prednisone (or equivalent) for at least 3 months Participation in a clinical trial in rheumatoid arthritis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>